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A B S T R A C T
Heavy users and addicted individuals have shown to develop an approach action tendency – or approach bias – toward stimuli related to the substance of interest.
Emerging evidence points to approach bias retraining (ABR) as an eﬀective aid for the treatment of addictive behaviors. The current study seeks to extend this work
by testing, in a pilot study, whether standard smoking cessation treatment involving cognitive-behavioral therapy (CBT) and nicotine replacement therapy can be
augmented by ABR. To this end, we will randomly assign 100 adult smokers to either ABR-augmented treatment or placebo-augmented treatment and compare the
two conditions on short-term and long-term abstinence rates. The hope is that the ﬁndings of this study can inform treatment development for adult smokers.
1. Introduction
Cigarette smoking remains the most preventable cause of death in
the United States [1]. Combination interventions (e.g., cognitive be-
havioral therapy [CBT] plus nicotine replacement therapy [NRT]) are
eﬀective but associated with high relapse rates [2]. Hence, there is a
need for new, innovative smoking cessation strategies that can engage
core mechanisms implicated in the maintenance and cessation of
smoking [2].
Consistent with incentive-sensitization theory [3], dual process
models of addiction posit that repeated drug use sensitizes automated
impulsive, implicit processes [4,50]. Speciﬁcally, because drug-related
cues become a signal of reward over time, heavy users and addicted
individuals develop an approach action tendency – or approach bias –
toward stimuli related to the substance of interest [4,5].
Among diﬀerent assessment strategies, the Approach-Avoidance
Task (AAT [6]; has emerged as a suitable tool for assessing approach
bias [7]. This 15-min computerized task instructs participants to use a
joystick to either pull toward themselves or push away from themselves
images presented on the screen that vary in content (i.e., substance-
related, neutral, positive) and format (e.g., right- or left-tilted). Speci-
ﬁcally, using indirect task instructions (i.e., responding to the format
instead of content), participants are told that all pictures will be slightly
tilted to the left or right, and that they are to pull right-tilted pictures
and push left-tilted pictures. Importantly, pulling the joystick increases
the size of the image, while pushing the joystick decreases the size of
the image, thus causing visual approach and avoidance eﬀects, re-
spectively. The AAT involves multiple trials and records reaction times
(RT) for each trial. The RTs for each trial are then used to compute an
index of approach bias – i.e., the relative tendency to pull rather than to
push in response to the presentation of substance-related images [8,9].
Using the AAT, researchers have shown that approach bias is evident in
problem users of alcohol [4,10,11] and cannabis [8] as well as cigarette
smokers [4,12,13], although there are studies that have not observed
the relation between substance use problems and approach bias [9].
Manipulating approach bias – or training persons with substance use
problems to push away substance-related images – has shown promise
for enhancing outcomes of substance use treatments [4,11,14–16].
Approach bias retraining involves repeated administrations (sessions)
of a modiﬁed AAT, which involves changing the contingencies of the
AAT assessment task ensuring that participants learn to engage in
avoidance (pushing the joystick) when presented with substance-use
related pictures. In the treatment of alcohol use disorder, an initial
study involving 214 inpatients receiving CBT showed that, compared to
those who received no training or 4 sessions of a control intervention
(i.e., repeated AAT assessment tasks involving equal number of
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avoidance and approach movements to alcoholic and non-alcoholic
drinks), participants assigned to receive 4 sessions of approach bias
retraining evidenced signiﬁcantly lower relapse rates at 1-year follow-
up [11]. Importantly, this ﬁnding was replicated and extended in a
larger sample (N=509), indicating approximately a 10% reduced re-
lapse rate in training vs. control and evidence of reductions in approach
bias mediating the clinical eﬀect [14].
Building upon this research, we recently completed a pilot study
[17] involving adult smokers motivated to make a quit attempt
(N=52) and tested (1) whether 4 sessions of approach bias retraining
would reduce approach bias (i.e., target engagement) and (2) whether
target engagement would be associated with the numbers of days quit
in the week following an unaided and self-guided quit attempt (i.e.,
initial estimate of eﬃcacy; [18]. Data supported both hypotheses and
provided evidence for a small, albeit statistically non-signiﬁcant, eﬀect
of training on days quit in the week following the quit attempt [17].
Together, these promising ﬁndings support next-stage research aimed
at evaluating approach bias retraining to aid standard smoking cessa-
tion interventions.
Mechanistic research is critical for optimizing interventions [19].
Hence, although the primary aim of this study is to examine whether
approach bias retraining can aid smoking cessation, we will test whe-
ther the eﬀect of approach bias retraining on abstinence is in fact ac-
counted for by a reduction in approach bias (i.e., target engagement).
Consistent with incentive-sensitization theory [3], initial research in
smokers shows that approach bias covaries with self-reported craving
[4] and research in alcohol use disorders shows that approach bias
retraining reduces craving [11,14,20]. Because reduced craving has
been shown to mediate other treatments for smoking cessation [21,22],
we will also test whether reduced craving mediates the relation be-
tween reduced approach bias and abstinence. Finally, recognizing that
the eﬃcacy of interventions and their mechanisms may vary as a result
of individual diﬀerences [19], we will explore the potential moderator
eﬀect of nicotine dependence, which has been related to approach bias
[23] and smoking cessation outcomes [24], respectively, as well as sex,
consistent with priorities of the NIH.
2. Methods
2.1. Study design
Adult smokers (N = 100) will be randomly assigned to either (1) 7
weeks of standard smoking cessation treatment involving CBT and NRT
(standard treatment [ST]) integrated with approach bias retraining
(ST + ABR) or (2) ST integrated with sham training (ST + CTRL).
Smoking status will be assessed at baseline, during the treatment
period, and during the post-treatment period at weeks 8, 9, 13, and 17.
2.2. Speciﬁc aims
1. To assess, in a randomized clinical trial, the eﬀects of ST + ABR vs.
ST + CTRL on the following smoking cessation outcomes: Short-
and long-term point prevalence abstinence (PPA) and prolonged
abstinence (PA). We hypothesize that PPA and PA will be higher,
both in the short term and long term, for those in the ST + ABR
condition than for those in the ST + CTRL condition. We further
hypothesize that the rate of decline in abstinence over time will be
smaller in the ST + ABR condition than for those in the ST + CTRL
condition.
2. To examine potential mechanisms of action. In testing the putative
mechanisms of action, we hypothesize that a reduction in approach
bias mediates the eﬀects of the intervention on abstinence.
Additionally, we will explore the role of reduced cravings as a me-
chanism underlying the approach bias-abstinence relation. We fur-
ther hypothesize that reduced craving mediates the relation between
reduced approach bias and abstinence. To determine possible
moderators, we will test whether the eﬃcacy and mechanisms vary
as a function of nicotine dependence and sex, respectively.
2.3. Participants
Participants will be 100 adult smokers between the ages of 18 and
64, who have been smokers for at least one year, and smoke at least 5
cigarettes per day. Participants must report a motivation to quit
smoking of at least a 5 on a 10- point scale and must also be willing and
able to commit to a 17-week protocol.
In order to reduce the risk of adverse events, we will employ the
following exclusion criteria: (1) a lifetime history of bipolar disorder,
schizophrenia, or psychosis; (2) an eating disorder in the last 6 months;
(3) an alcohol or substance abuse disorder in the last 6 months; (4)
visual or hand-motoric impairments; (5) use of other tobacco products;
(6) current use of any other pharmacotherapy or psychotherapy for
smoking cessation not provided by the researchers during the quit at-
tempt.
3. Procedures
The study is funded by the National Institute on Drug Abuse (NIDA;
R34DA044431) and is registered on clinicaltrials.gov (ID:
NCT03325777). The Institutional Review Board of the University of
Texas at Austin approved the study and a Data Safety and Monitoring
Board provides ongoing oversight. The study is currently in the re-
cruitment phase.
3.1. Screening
We will employ a variety of recruitment strategies to direct inter-
ested individuals to an online prescreen using REDCap (Research
Electronic Data Capture), an electronic database hosted at the
University of Texas at Austin. The prescreen will assess basic study
entry criteria, and individuals who pass the initial screen will advance
to a clinical phone interview. The DSM-IV edition of the Mini
International Neuropsychiatric Interview (MINI) [25] will be used to
assess for exclusionary criteria. MINIs will be conducted exclusively by
highly trained study staﬀ with at least a bachelor's degree and will be
supervised by the principal investigator. MINI phone screenings will be
supervised and reviewed on a weekly basis to ensure quality control
and rater competency. Eligibility screenings and clinical interview data
will be stored in REDCap.
3.2. Enrollment/randomization
If eligible following the MINI, participants will schedule a baseline
session at UT Austin. Upon enrollment, eligible participants will be
randomized to either ST + ABR or ST + CTRL condition. The project
biostatistician will generate the randomization using variable-sized
permuted block-randomization, with block sizes varying from 4 to 12.
Randomization will be stratiﬁed by sex and scores on the Test for
Nicotine Dependence (TND) (i.e., 1–4 indicative of low to moderate
dependence vs. 5–10 as moderate to high dependence). The participants
will be blind to study condition. Prior to any baseline assessment,
participants will receive an online consent form outlining the details of
the study, potential risks and beneﬁts of participation, and the proce-
dures they will undergo if they choose to participate. Research staﬀ will
address concerns and answer any questions the potential participant
may have about the study. Once the individual signs the online consent
form, he/she will be cleared for the baseline visit.
During this baseline visit, participants will be asked to complete
baseline assessment measures. At the beginning of the baseline session,
participants will be introduced to the program's cessation goals and
reminded of intervention procedures and timeline. Lastly, participants
will be oriented to and instructed to complete a baseline assessment of
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approach bias for smoking stimuli with the AAT (see below).
3.3. Interventions
Standard Smoking Cessation Treatment + Approach Bias Retraining
(ST + ABR). Consistent with the manualized procedures we have em-
ployed in past and ongoing NIDA-funded investigations [26–29], the
standard intervention (ST) involves a combination of CBT plus NRT. As
outlined in the therapist manual, CBT will involve 45-min weekly ses-
sions over a 7-week period. Weeks 1–4 focus on preparing participants
for their quit day, which is scheduled for the beginning of week 5. The
study therapists will cover topics such as smoking and abstinence his-
tory, individualized smoking cessation barriers, maladaptive cognitions
around the use of cigarettes, using cigarettes as a way to cope with
stress and negative aﬀect, and identifying and planning for triggers and
high-risk situations. Therapy sessions will be conducted by trained
study staﬀ supervised weekly by the second author. All sessions will be
audio recorded and 10% will be rated by independent raters to ensure
therapist adherence to the treatment protocol. Participants will be
provided with speciﬁc instructions on how to use the Nicoderm CQ(R),
24-h transdermal nicotine patches, starting on their quit date. We will
provide 8-weeks’ worth of nicotine patches consistent with guidelines
[2].
Each of the treatment sessions following baseline will begin with a
15-min ABR task. Participants in the ST + ABR condition will be told
that the computerized training is designed to complement the beha-
vioral counseling by weakening automatic cigarette-approach and
strengthening automatic cigarette-avoidance. Participants will be in-
structed to pull or push the joystick depending on the tilt of the picture
(i.e., right-tilted vs. left-tilted). Each training session will start with a
short assessment phase of 48 trials (12x pull smoking, 12x push
smoking, 12x pull positive, 12x push positive). We will use this as-
sessment phase to calculate an approach bias score at the start of each
ABR training session, allowing us to measure the change in approach
bias over time. This will be followed by the training phase of 192
training trials consisting of 96 positive pictures with the to-be-pulled tilt
and 96 smoking images with the to-be-pushed tilt. Accordingly, in these
trials participants will always avoid smoking-related images and always
approach positive images.
Standard Smoking Cessation Treatment + Sham Training
(ST+ CTRL). Participants assigned to the ST + CTRL condition will be
prescribed identical standard care to that of the experimental group.
The two groups diﬀer only in the computerized training they will re-
ceive. In order to create comparable expectancy eﬀects and enhance
experimental control, we will provide participants assigned to this
training condition with a highly plausible rationale for augmenting
standard smoking cessation. Similar to our pilot study examining ABR
for smoking cessation and our other past work examining ABR for
preventing relapse in alcohol use disorder, we will tell participants that
the computerized training weakens the automatic tendency to approach
cigarettes by improving control over this automatic tendency (e.g.,
learning to ignore urge to approach and respond only to task instruc-
tions) and that following the training, they will easily be able to ap-
proach or avoid regardless of image content [17]. They also will be
instructed to pull or push the joystick depending on the tilt of the
picture (i.e., pull right-tilted vs. push left-tilted). However, instead of
avoiding all smoking-related pictures, participants in the ST + CTRL
condition will pull and push all pictures equally often. This yields an
assessment phase of 48 trials (12x pull smoking, 12x push smoking, 12x
pull positive, 12x push positive) and 192 training trials consisting of 96
images tilted to the right and 96 images tilted to the left.
3.4. Post-treatment follow-up
Participants will be asked to attend brief 10–15-min follow-up ses-
sions at weeks 8, 9, 13, and 17 (see Table 1). The study staﬀ will check
in with participants regarding self-reported smoking status and collect
biochemical veriﬁcation measures. In the event that participants are
unable to attend lab follow-visits, study staﬀ will contact participants to
collect self-report smoking status assessments.
4. Assessments
4.1. Screening
Demographics. Participants will be asked to provide standard de-
mographic information (i.e. name, contact information, age, sex, race/
ethnicity, level of education, etc.).
Smoking History Questionnaire (SHQ). Smoking history and pattern
will be assessed with the SHQ, a 30-item measure that includes items
pertaining to smoking rate, age of initiation, years of being a habitual
smoker [30]. This measure will serve to contextualize the participants’
smoking behavior and history at intake.
Test for Nicotine Dependence (FTND). The FTND is a 6-item scale
designed to assess gradations in tobacco dependence [31]. This measure
will serve to quantify nicotine dependence, which will be used as a
covariate in the primary analyses.
Motivation to Quit. Participants will be asked to self-report their
motivation to quit smoking cigarettes on a 10-point Likert scale, with 1
being not at all motivated to 10 being extremely motivated.
MINI International Neuropsychiatric Interview (MINI). The MINI is a
short structured clinical interview for diagnosis of psychiatric disorders
according to DSM-IV [25]. The MINI will be administered by trained
research personnel with a B.S. or B.A. in psychology and will be su-
pervised by the doctoral-level staﬀ. Modules B-Suicidality, C-Manic
Episode, I-Alcohol Dependence and Abuse, J-Substance Dependence
and Abuse, K-Psychotic Disorders, L-Anorexia Nervosa, M-Bulimia
Nervosa, and O-Medical, Organic, Drug Cause Ruled Out will be used to
assess exclusionary criteria.
4.2. Smoking status
As in past and ongoing work [26–29], self-reported smoking status
will be assessed during the intervention (weeks 0–7), at posttreatment
(week 8), and at 1-month (week 9), 2-month (week 13) and 3-month
(week 17) follow-up (i.e., post-quit). Self-reported abstinence will be
veriﬁed by expired carbon monoxide (CO). Abstinence at the 2-month
(week 13) and 3-month (week 17) follow-up will additionally be ver-
iﬁed with saliva cotinine. We will use the timeline follow-back (TLFB)
procedure at all assessments to assess daily cigarette consumption; this
procedure has demonstrated good reliability and validity [32]. Self-
reported abstinence will be overridden by a positive carbon monoxide
(> 4 ppm) [33] or saliva cotinine veriﬁcation (> 10 ng/mL) [34]. If
neither CO nor cotinine levels are available to verify abstinence at an
assessment, abstinence will be considered missing data [35]. We will
employ 7-day point prevalence abstinence (PPA) and prolonged ab-
stinence (PA) as the primary outcomes. PPA will be deﬁned as no
smoking, not even a puﬀ, in the 7 days prior to any assessment. Failure
to maintain PA at any assessment will be deﬁned by smoking on 7
consecutive days or smoking at least once each week over 2 consecutive
weeks [36].
4.3. Approach bias
Assessment.We will administer the AAT [13,17,37] in order to assess
approach bias at baseline. The AAT instructs participants to pull a
joystick upon seeing an image tilted to the right and to push the joystick
upon seeing a left-tilt image, while ignoring the image content (i.e.,
indirect instructions). By pulling the joystick (approach), the picture
grows in size; by pushing the joystick away (avoidance), the picture
shrinks. The AAT includes 96 trials in which each of 24 smoking-related
pictures (e.g., woman lighting a cigarette) and each of 24 positive
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images (e.g., group of friends exercising) will be pulled and pushed. We
selected positive stimuli because there are no intuitive control stimuli to
cigarettes (like there is for alcohol; i.e., non-alcoholic beverages) and
this set of images has been successfully used in other pilot work by
members of our research group [17].
Scoring. An approach bias score for smoking-related pictures will be
computed for each participant by subtracting the average time it takes
to pull smoking-related images from the average time it takes to push
away these images. Thus, a positive value indicates an approach ten-
dency toward smoking stimuli, whereas a negative value is indicative of
avoidance of smoking images.
Furthermore, each training session will begin with a short assess-
ment phase of 48 trials (12x pull smoking, 12x push smoking, 12x pull
positive, 12x push positive). This assessment phase will be used to
calculate an approach bias score at the start of each ABR training ses-
sion, thus allowing our group to measure any changes in approach bias
across protocol weeks. Finally, we will explore scoring algorithms for
the AAT and session data that standardize the bias scores by dividing an
individual's diﬀerence in response times by a personalized standard
deviation of these response latencies. A similar scoring approach has
been used successfully for a related task, the Implicit Association Test
(IAT; [38].
4.4. Craving
The Questionnaire of Smoking Urges (QSU) is a 10-item measure
that assesses urges and cravings for cigarettes [39]. We will administer
this measure at baseline, weekly throughout treatment, and at the
follow-up assessments.
4.5. Participant adherence and incentives for participation
We will utilize a number of strategies in eﬀorts to promote ad-
herence and retention. Prior to randomization, participants will have
completed an extensive screening process. Participants will also be
provided a document informing them of the study expectations. Staﬀ
will manage retention of the participants. If a participant misses a
session, staﬀ will call to check in, encourage attendance, and help
problem solve if a barrier to participation is present. Staﬀ will also
monitor adherence to the assessment schedule and will place reminder
calls/emails to participants three days prior to each scheduled follow-
up session.
Finally, we will provide $250 per individual (i.e., $50 for
completing each major outcome assessment; weeks 0, 6, 9, 13, and 17)
as an incentive for participation in the study. We think this amount is
appropriate given the amount of time required for completing the as-
sessments.
5. Data analysis
5.1. Overview
The primary objective of this project is to estimate the eﬀect size for
the advantage of ST + ABR over ST + CTRL for smoking cessation. At
the same time, we are aware of the dangers of relying on small-scale
pilot studies to assess the potential of novel treatment approaches [40]
because the eﬀect size estimates have a large standard error. We believe
that a sample size of 100 is more than suﬃcient to provide adequate
estimates of the intervention eﬀect size, while staying within the scope
of a developmental project. We recognize that small eﬀect sizes will not
be detectable as signiﬁcant with a sample of this size.
We will ﬁrst assess the equivalence of the treatment groups on key
baseline variables (demographics and psychological variables); vari-
ables on which the groups diﬀer will be used as covariates in the ﬁnal
analyses. We will then examine missing data patterns, dropout rates
(see below), and distributional properties of measures, and use trans-
formations to improve distributions if necessary.
Abstinence data (PPA and PA) will be analyzed using multivariate
Generalized Linear Mixed Models (GLMM), employing the program
HLM 7.0 with a logistic linking function (see below for details of the
model). GLMM includes all subjects, regardless of missing data, and
does not require imputation of missing data (e.g., missing data is not
automatically coded as smoking, as in last-observation-carried-forward
analyses [35]. This is the recommended intent-to-treat approach for
longitudinal smoking cessation trials [41].
We will use multivariate GLMM (with PA and PPA as the multiple
dependent variables [DVs]) because multivariate mixed models have
greater power than univariate mixed models [42], and because as-
sessments at each time point are included as long as at least one of the
DVs is available at that time point. Thus, multivariate GLMM in-
corporates all available data from all DVs. In addition, since performing
a single multivariate analysis obviates the need for the use of a con-
servative p-value to correct for the false discovery rate when per-
forming multiple univariate tests of each DV, this multivariate GLMM
allows us to maximize power without increasing the false discovery
rate. Hereafter, when we use the general term “abstinence” it will refer
Table 1
Assessment schedule.
Protocol weeks
> -1 0 1–4 5 6 8 9–17
End points
Pre-screen Baseline Pre-Quit Quit Week 1-Week Follow-Up Post-treatment 1-, 2-, 3- Month Follow-Up
Screening
Demographics X
Smoking history (SHQ) X
Motivation to quit X X X X X X X
Nicotine dependence (FTND) X
Psychiatric diagnosis and suicide (MINI) X
Aim 1: Eﬃcacy
Timeline follow-back X X X X X X
Carbon monoxide X X X X X X
Saliva cotinine Xa
Aim 2: Mechanisms of Action
Craving (QSU-B) X X X X
Approach Bias (AAT; session data) X X X X
a Only assessed at 2- and 3- month follow-up.
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to the multivariate outcome of PPA and PA together.
As in previous research [26–28], we will use a 3-phase piecewise
growth curve model to track PPA and PA over the 17 week study
period. The ﬁrst phase of the growth model consists of weeks 0–5 (pre-
quit treatment phase), the second phase will be weeks 6–8 (post-quit/
treatment phase), and the third phase will be from weeks 8–17 (post-
treatment phase). Modeling the growth curve starting at week 0 is
necessary for intent-to-treat analyses. We will model the change over
time as linear within each phase, and model a discontinuity in the
growth curve between the ﬁrst and second phase to reﬂect the expected
eﬀects of the scheduled quit day during week 5. We will use the
parameterization of piecewise models described by Singer and Willett
(2003). Thus, the models will include a Time variable for each phase of
the model (Time1, Time2, and Time3), each of which is coded to reﬂect
weeks since baseline during each phase, and a dichotomous variable
(coded 1 for weeks 0–5, and 0 for weeks 6–17) to code the discontinuity
between phase1 and phase 2 (see Singer and Willett, 2003). All the
Time variables, the discontinuity variable, and the intercept will have
random eﬀects. Non-signiﬁcant random eﬀects will be dropped. The
models will also include treatment condition and its interactions with
each Time variable and with the discontinuity variable. Demographics,
baseline nicotine dependence, and any baseline psychological variables
on which treatment conditions diﬀer, will also be included as covariates
(and retained if signiﬁcant). Finally, in order to explore whether dose
predicts abstinence, and to reduce variance in abstinence related to
treatment dose, we also will include attendance, and the atten-
dance× condition interaction, as terms in the GLMM models and as
moderators of the slopes during each phase of the study. Since the
primary end-point is the 3-month follow-up, all Time variables will be
centered at the 3-month follow-up so that treatment condition diﬀer-
ences will reﬂect diﬀerences at the 3-month follow-up. Our secondary
endpoint is post-treatment.
In order to minimize Type II error, provide a more parsimonious
model that ﬁts the data, and to more clearly elucidate the signiﬁcant
relations between the predictors and abstinence, we will recompute the
ﬁnal model after removing non-signiﬁcant interaction terms [43,44].
5.2. Aims
Aim 1a (ST + ABR will engender higher abstinence rates (PPA and
PA as multivariate DVs) at post-treatment and at the 3-month follow-
up, compared to ST + CTRL)
In two multivariate GLMM analyses, we will alternately “center” our
Time variables at 1) the 3-month follow-up or at 2) post-treatment, to
estimate between-group diﬀerences at these respective end points,
which will be indicated by the treatment condition main eﬀect in each
analysis. If signiﬁcant in an analysis, the treatment condition eﬀect will
demonstrate that abstinence rates are signiﬁcantly diﬀerent between
the treatment conditions at the respective end point. In addition, we
expect slopes of decrease in abstinence after quit week (in phases 2 and
3) to be steeper (worse) in ST + CTRL compared to ST + ABR (the
Condition × Time interaction).
Aim 1b (Mean time to ﬁrst lapse and to relapse to be greater for
those in the ST + ABR condition than for those in the ST + CTRL
condition)
We will use Cox proportional hazard models to assess the between-
group diﬀerence in time to lapse and time to relapse.
Aim 2a (Greater abstinence in ST + ABR compared to ST + CTRL
will be partially mediated by reductions in approach bias)
We will use multilevel modeling (MLM) instead of GLMM to cal-
culate the “a” path in our mediation model (the eﬀect of treatment on
approach bias) because the outcome for the “a” path is continuous. The
“b” path in our mediation model will be the regression coeﬃcients for
approach bias when it is added to the multivariate GLMM analysis
predicting abstinence (the model in Aim 1a). In order for the “b” path to
more closely estimate the causal relation between approach bias and
abstinence, we will use a cross lag mediation analysis, in which the
mediator at time “t” predicts the outcome at the next assessment (“t
+1”), controlling for the outcome at time “t” (as we have done in
previous multimediator longitudinal models [45]). Further, for accurate
calculation of the cross lag eﬀects, recent research [46–48] indicates
that one must disaggregate the between-person and within-person
components of the time-varying predictor (i.e., the mediator), but still
estimate both eﬀects in the same model. Thus, we will include both
between- and within-person eﬀects of all mediators in our models. The
signiﬁcance of the mediated pathway (and all mediated pathways in
this grant) will be calculated using the distribution of products test
performed by the program RMediation [49].
Aim 2b (Craving will mediate the eﬀect of approach bias on ab-
stinence)
We will calculate the “a” path in this mediation analysis by calcu-
lating the disaggregated cross lag eﬀect of approach bias at time “t” on
craving at time “t+1”, controlling for craving at time “t” (we must
calculate the cross lag eﬀect for the “a” path in this analysis because
approach bias is not randomized). The “b” path will be calculated using
disaggregated cross lag mediation analysis, with craving at time “t” and
abstinence at time “t” predicting abstinence at time “t+1”.
Aim 2c (Sex and nicotine dependence as moderators of treatment
eﬀects)
To determine whether sex moderates the eﬀect of condition on
abstinence, we will add interactions between sex and all of the growth
curve parameters in the multivariate GLMM piecewise growth curve
model testing Aim 1a. Any signiﬁcant interaction will indicate that
there are sex diﬀerences in that portion of the piecewise growth curve.
To investigate if mediation depends on sex, we will add the interaction
of sex with the “a” path, the “b” path, and the “c’” path in our mediation
model in Aim 2a. If moderation is signiﬁcant, we will calculate the
signiﬁcance of the mediated pathway for males and for females, sepa-
rately. We will use a similar approach to investigate nicotine depen-
dence as a moderator.
5.3. Missing data
We will use pattern mixture modeling to assess the eﬀect of missing
data. We will rerun our analyses coding for various missing data pat-
terns (no missing data, sporadic missing, dropouts, etc.) to determine
(1) if missingness impacts our ﬁndings and (2) how the diﬀerences
between treatment conditions depends on the missing data pattern.
5.4. Statistical power
Aim 1a We performed a Monte Carlo study to calculate the
minimum between-group diﬀerences in abstinence rates detectable by
our analysis. For this study, we conservatively assumed an average of 8
assessments per participant (73% of the assessments) for the 100 par-
ticipants and a 20% smoking abstinence rate in ST + CTRL at the 3-
month follow-up. We examined numerous abstinence rates for
ST + ABR to determine the lowest rate detectable by our analysis with
0.80 power, performing 1000 simulations for each tested abstinence
rate. The results indicated that we would have greater than 0.80 power
to detect a signiﬁcant condition eﬀect if the abstinence rate in
ST + ABR was 42% or greater (eﬀect size ω=.238). This between-
group diﬀerence is between a small (ω=.10) and a medium (ω=.30)
eﬀect size.
Aims 2a and 2b Our Monte Carlo study indicated that we would
have greater than 0.84 power to detect mediation for a mediated
pathway if the “a” path and the “b” path were of medium eﬀect size or
greater.
Aim 2c. For the exploratory aim of sex (or nicotine dependence)
moderating the eﬀects of condition on abstinence, again we would have
0.80 power to detect an eﬀect size of ω=.238, since adding the sex
interaction terms just decreases the degrees of freedom for the
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signiﬁcance tests very slightly. Similarly, the power to detect medium
sized-mediated pathways is just slightly decreased by having additional
sex interactions in the model. In this case, we have 0.83 power to detect
a mediated pathway if both the “a” and “b” paths are medium eﬀect
sizes or greater.
6. Discussion
Smoking remains a signiﬁcant public health problem and there is a
need for more eﬀective interventions. Theory and initial empirical
ﬁndings justify testing whether a simple computerized intervention
targeting the approach action tendency – or approach bias – toward
stimuli related to cigarette smoking can augment existent smoking
cessation treatments. The goal of the current research is to evaluate the
potential eﬃcacy of an intervention that integrates this computerized
intervention with standard smoking cessation care. The proposed study
represents a crucial and important stage in translating basic research to
strategies for treating nicotine dependence. The investigation addresses
an important public health issue by testing an integrated intervention -
informed by basic research - that may lead to a more eﬀective treatment
for at-risk smokers while simulatenously isolating explanatory me-
chanisms. The expected ﬁndings should: (1) guide advances in the
theoretical conceptualization of the mechanisms involved in smoking;
and (2) provide initial eﬀect size data for the integrated smoking ces-
sation intervention, and thus provide the necessary data for a large-
scale follow-up trial.
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